Novo Nordisk’s top-selling diabetes drug Victoza cut the risk of heart attack, stroke and cardiovascular death by 13 percent in a closely watched study, but the result disappointed investors who had hoped for more.
The stock fell around 5 percent in Copenhagen on Tuesday.
Victoza is only the second diabetes drug to show such heart benefits, after Eli Lilly and Boehringer Ingelheim’s pill Jardiance.
Source: Reuters
Filed Under: Drug Discovery
